1. Home
  2. JHI vs SPRO Comparison

JHI vs SPRO Comparison

Compare JHI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Investors Trust

JHI

John Hancock Investors Trust

HOLD

Current Price

$13.72

Market Cap

123.7M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.34

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JHI
SPRO
Founded
1971
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
123.7M
136.7M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
JHI
SPRO
Price
$13.72
$2.34
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
29.5K
342.0K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
6.80%
N/A
EPS Growth
N/A
N/A
EPS
1.05
N/A
Revenue
N/A
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.63
$0.51
52 Week High
$13.40
$3.22

Technical Indicators

Market Signals
Indicator
JHI
SPRO
Relative Strength Index (RSI) 39.32 49.98
Support Level $13.93 $2.26
Resistance Level $14.21 $2.39
Average True Range (ATR) 0.12 0.08
MACD -0.02 -0.00
Stochastic Oscillator 18.06 62.50

Price Performance

Historical Comparison
JHI
SPRO

About JHI John Hancock Investors Trust

John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: